|
|
Volumn 4, Issue 5, 2003, Pages 320-322
|
|
Iometopane. 123I β-CIT, Dopascan injection, GPI 200, RTI 55
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER;
ANTIPARKINSON AGENT;
BIOLOGICAL MARKER;
CARRIER PROTEIN;
COCAINE;
CONTRAST MEDIUM;
DOPAMINE BINDING PROTEIN;
DOPAMINE RECEPTOR STIMULATING AGENT;
DOPAMINE TRANSPORTER;
DOPAMINE-BINDING PROTEIN;
DOPASCAN;
DRUG DERIVATIVE;
GPI 1485;
GPI 200;
IODINE 123;
IOMETOPANE;
PLACEBO;
PSYCHOTROPIC AGENT;
RADIOACTIVE IODINE;
RADIOPHARMACEUTICAL AGENT;
TROPANE DERIVATIVE;
UNCLASSIFIED DRUG;
ARTICLE;
ASIA;
AUSTRALIA;
AUSTRIA;
BELGIUM;
BRAIN RADIOGRAPHY;
CANADA;
CAUDATE NUCLEUS;
CELL LOSS;
CLINICAL STUDY;
CLINICAL TRIAL;
COMPUTER ASSISTED TOMOGRAPHY;
CONTRACT;
CORPUS STRIATUM;
DENMARK;
DIAGNOSTIC ACCURACY;
DIAGNOSTIC IMAGING;
DIAGNOSTIC PROCEDURE;
DIFFERENTIAL DIAGNOSIS;
DISEASE COURSE;
DISEASE SEVERITY;
DOPAMINERGIC NERVE CELL;
DRUG APPROVAL;
DRUG BINDING;
DRUG EFFICACY;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG UPTAKE;
EARLY DIAGNOSIS;
ESSENTIAL TREMOR;
EUROPE;
EUROPEAN UNION;
FINLAND;
FOOD AND DRUG ADMINISTRATION;
FRANCE;
GERMANY;
GREECE;
HUMAN;
IMAGING SYSTEM;
INTRAVENOUS DRUG ADMINISTRATION;
ISOTOPE LABELING;
ITALY;
JAPAN;
KOREA;
LICENCE;
LIECHTENSTEIN;
LONGITUDINAL STUDY;
LUXEMBOURG;
METABOLISM;
NERVE CELL DEGENERATION;
NETHERLANDS;
NEUROCHEMISTRY;
NONHUMAN;
NORWAY;
NUCLEAR MAGNETIC RESONANCE IMAGING;
PARALYSIS;
PARKINSON DISEASE;
PATENT;
PHARMACODYNAMICS;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROGRESSIVE SUPRANUCLEAR PALSY;
PUTAMEN;
SCINTISCANNING;
SENSITIVITY AND SPECIFICITY;
SIDE EFFECT;
SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;
SPAIN;
SWEDEN;
SWITZERLAND;
SYNAPTOSOME;
TAIWAN;
TREMOR;
UNITED KINGDOM;
UNITED STATES;
|
|
EID: 0141615679
PISSN: 11745886
EISSN: None
Source Type: Journal
DOI: 10.2165/00126839-200304050-00008 Document Type: Article |
|
Times cited : (4)
|
|
References (3)
|
